Guardant Health (GH) now expects full year 2024 revenue to be in the range of $720 to $725 million, representing growth of 28% to 29% compared to full year 2023. This compares to the prior range of $690 to $700 million, representing growth of 22% to 24%. Guardant Health continues to expect full year 2024 non-GAAP gross margin excluding screening to be in the range of 61% to 63% and total non-GAAP operating expenses to be in the range of $720 to $730 million, representing a flat to 1% decrease compared to 2023. Guardant Health now expects free cash flow to be in the range of $(265) to $(275) million in 2024, representing an improvement of $70 million to $80 million compared to 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target lowered to $35 from $40 at Bernstein
- Guardant Health Appoints Roberto Mignone to Board
- Guardant Health price target lowered to $50 from $60 at Leerink
- Guardant Health publishes SCRUM-Japan GOZILA study results
- Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI